Skip to main content

Prometheus Biosciences, Inc. (RXDX)

NASDAQ: RXDX · IEX Real-Time Price · USD
29.88 -0.75 (-2.45%)
Nov 29, 2021 4:00 PM EST - Market closed

Company Description

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD).

Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD.

The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr.

Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019.

The company was founded in 2016 and is based in San Diego, California.

Prometheus Biosciences, Inc.
CountryUnited States
Founded2016
IPO DateMar 12, 2021
IndustryBiotechnology
SectorHealthcare
Employees24

Contact Details

Address:
9410 Carroll Park Drive
San Diego, CA 92121
United States
Phone858 824 0895
Websiteprometheusbiosciences.com

Stock Details

Ticker SymbolRXDX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$19.00
CIK Code1718852

Key Executives

NamePosition
Mark C. McKennaPresident, Chief Executive Officer and Chairman
Dr. Keith W. Marshall M.B.A., MBA, Ph.D.Chief Financial Officer and Treasurer
Mark StenhouseChief Operating Officer
Dr. Allison Luo M.D.Chief Medical Officer
Gerald T. ProehlAdvisor
Dr. Olivier Laurent Ph.D.Chief Technology Officer
Dr. Laurens Kruidenier Ph.D.Chief Scientific Officer
Noel KurdiVice President of Investor Relations and Communications
Timothy K. Andrews Esq.General Counsel and Secretary
Nori EbersoleChief People Officer

Latest SEC Filings

DateTypeTitle
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 16, 20214Statement of changes in beneficial ownership of securities
Nov 12, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 12, 20218-KCurrent report
View All SEC Filings